Masimo (MASI)
(Delayed Data from NSDQ)
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$114.27 USD
-0.78 (-0.68%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $114.34 +0.07 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth D Momentum B VGM
Zacks News
DexCom (DXCM) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Buoyed by a solid second quarter, Masimo (MASI) raises its 2019 guidance.
Masimo (MASI) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 4.11% and 3.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More
by Zacks Equity Research
Solid growth in emerging markets is expected to be an added positive this earnings season.
Masimo (MASI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Masimo's (MASI) recent developments likely to show on second-quarter results.
Masimo (MASI) Q2 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Masimo (MASI) Hits a 52-Week High on Solid Growth Drivers
by Zacks Equity Research
Masimo (MASI) gains from expansion of product portfolio and recent regulatory approvals.
Here's Why You Should Add Bruker (BRKR) to Your Portfolio
by Zacks Equity Research
Investor confidence in Bruker stock (BRKR) is high on substantial potential of MALDI Biotyper.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) receives FDA clearance for its O3 Regional Oximetry for utilization on neonatal and infant patients.
Near-Term Outlook for Medical Instruments Industry Bleak
by Urmimala Biswas
Complex regulatory hurdles come in the way of any infrastructural or technology growth in the Medical Instruments space.
DaVita Divests DMG to Optum, Boosts Kidney Care Services
by Zacks Equity Research
The divestment of DMG boosts DaVita's (DVA) core Kidney Care business.
Here's Why You Should Hold PerkinElmer (PKI) Stock for Now
by Zacks Equity Research
PerkinElmer (PKI) raises earnings per share guidance for 2019.
Merit Medical Acquires Brightwater Medical for $35 Million
by Zacks Equity Research
The Brightwater Medical-acquisition broadens Merit Medical's (MMSI) product offerings.
Here's Why You Should Hold Baxter International (BAX) for Now
by Zacks Equity Research
Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.
Baxter's (BAX) New Sharesource 2.0 to Improve PD Treatment
by Zacks Equity Research
Baxter's (BAX) Sharesource 2.0 provides a more comprehensive patient treatment summary to enable faster clinical insights.
Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring
by Zacks Equity Research
Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.
Varian Medical Buys Endocare & Alicon to Boost Cancer Care
by Zacks Equity Research
Varian Medical (VAR) expects the buyouts to prove accretive to bottom line in fiscal 2020.
HealthEquity (HQY) Earnings & Revenues Top Estimates in Q1
by Zacks Equity Research
Higher revenues, solid segmental performance and expansion in margins benefit HealthEquity's (HQY) Q1 earnings.
Why Is Masimo (MASI) Down 2.9% Since Last Earnings Report?
by Zacks Equity Research
Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cooper Companies (COO) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Higher revenues, solid segmental performance and expansion in margins benefit Cooper Companies' (COO) Q2 earnings.
Veeva Systems (VEEV) Q1 Earnings Top Estimates, View Strong
by Zacks Equity Research
Veeva Systems (VEEV) issues strong guidance for fiscal 2020.
NextGen's (NXGN) Q4 Earnings Top Estimates, Bookings Down Y/Y
by Zacks Equity Research
NextGen (NXGN) Q4 results benefit from better performing recurring segment. However, gross margin contraction remains a woe.
Masimo's Technologies to be Deployed to Boost Pediatric Care
by Zacks Equity Research
NuVision's centers are to be equipped with Masimo's (MASI) SET, Root with Radical-7, NomoLine Capnography and Patient SafetyNet technologies.
Globus Medical Reveals Positive Study Results for ExcelsiusGPS
by Zacks Equity Research
Results of the study of ExcelsiusGPS reached a milestone for Globus Medical (GMED) in the field of robotics-assisted, minimally invasive pedicle screw placement procedure
Medtronic (MDT) Q4 Earnings Beat, Operating Margin Rises
by Zacks Equity Research
Excluding the Diabetes group, Medtronic (MDT) displays better performances at CER on the back of growth in rest of the business segments and across all geographies.